AR122125A1 - BINDING CONSTRUCTIONS TO MAGEB2 - Google Patents
BINDING CONSTRUCTIONS TO MAGEB2Info
- Publication number
- AR122125A1 AR122125A1 ARP210101368A ARP210101368A AR122125A1 AR 122125 A1 AR122125 A1 AR 122125A1 AR P210101368 A ARP210101368 A AR P210101368A AR P210101368 A ARP210101368 A AR P210101368A AR 122125 A1 AR122125 A1 AR 122125A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody construct
- mageb2
- polynucleotide
- vector
- furthermore
- Prior art date
Links
Abstract
La presente invención se refiere a una construcción de anticuerpo que comprende un dominio que se une a un péptido de MAGEB2 que forma complejo con un HLA y, opcionalmente, otro dominio que se une a CD3. Además, la invención proporciona un polinucleótido que codifica la construcción de anticuerpo, un vector que comprende dicho polinucleótido y una célula huésped transformada o transfectada con dicho polinucleótido o vector. Además, la invención proporciona un proceso para producir la construcción de anticuerpo de la invención, un uso médico de dicha construcción de anticuerpo y un kit que comprende dicha construcción de anticuerpo.The present invention relates to an antibody construct comprising a MAGEB2 peptide-binding domain complexed with an HLA and, optionally, another CD3-binding domain. Furthermore, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide, and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct, and a kit comprising said antibody construct.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027148P | 2020-05-19 | 2020-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122125A1 true AR122125A1 (en) | 2022-08-17 |
Family
ID=83218661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101368A AR122125A1 (en) | 2020-05-19 | 2021-05-19 | BINDING CONSTRUCTIONS TO MAGEB2 |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR122125A1 (en) |
-
2021
- 2021-05-19 AR ARP210101368A patent/AR122125A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38326A (en) | ANTIBODY CONSTRUCTS FOR CLDN18.2 AND CD3 | |
| BR112018001374A2 (en) | Bispecific antibody constructs that bind to egfrviii and cd3 | |
| UY35286A (en) | Antibody constructs for CDH19 and CD3 | |
| BR112018001531A2 (en) | cd70 and cd3 antibody constructs | |
| CL2021000716A1 (en) | Antibody constructs for flt3 and cd3. (divisional sol. 201800269) | |
| BR112018000475A2 (en) | Bispecific antibody constructs that bind to dll3 and cd3 | |
| CO2018000885A2 (en) | Bispecific antibody constructs that bind mesothelin and cd3 | |
| UY37928A (en) | ANTI-CD38 ANTIBODIES AND METHODS OF USE | |
| CL2017002641A1 (en) | Bispecific antibody constructs against cdh3 and cd3 | |
| AR119553A1 (en) | ANTIBODIES THAT BIND TO GPRC5D | |
| AR060241A1 (en) | COMPOSITIONS AND METHODS OF USE FOR C-MET ANTIBODIES | |
| DOP2023000158A (en) | TRIESPECIFIC ANTIBODY TARGETED BCMA, GPRC5D, AND CD3 | |
| AR122125A1 (en) | BINDING CONSTRUCTIONS TO MAGEB2 | |
| AR120093A1 (en) | ANTI-CEACAM ANTIBODIES AND USES THEREOF | |
| EA200901547A1 (en) | UNDEFINED REFRACTORY MATERIAL, METHOD FOR OBTAINING A GRANULAR REFLECTED REFRACTORY MATERIAL, AND ALSO APPLICATION OF REFORMED REFRACTIVE MATERIAL | |
| UY39224A (en) | BINDING CONSTRUCTIONS TO MAGEB2 | |
| UY39507A (en) | POLYPEPTIDE CONSTRUCTIONS THAT SELECTIVELY BIND CLDN6 AND CD3 | |
| AR105559A1 (en) | ANTIBODY CONSTRUCTS FOR CD70 AND CD3 | |
| EA201890336A1 (en) | DESIGNS OF BISPECIFIC ANTIBODIES CONNECTING WITH DPB3 (DLL3) AND KD3 (CD3) | |
| MY195946A (en) | Antibody Constructs for DLL3 and CD3 | |
| AR105560A1 (en) | ANTIBODY CONSTRUCTS FOR MSLN AND CD3 |